Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer

por Mishall, Katie M., Beadnell, Thomas C., Kuenzi, Brent M., Klimczak, Dorothy M., Superti-Furga, Giulio, Rix, Uwe, Schweppe, Rebecca E.
Publicado 2017

Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis

por Kessler, Brittelle E., Mishall, Katie M., Kellett, Meghan D., Clark, Erin G., Pugazhenthi, Umarani, Pozdeyev, Nikita, Kim, Jihye, Tan, Aik Choon, Schweppe, Rebecca E.
Publicado 2018